| Full text | |
| Author(s): Show less - |
Romualdo, Guilherme Ribeiro
[1, 2, 3]
;
Leroy, Kaat
[4]
;
Costa, Cicero Julio Silva
[1]
;
Prata, Gabriel Bacil
[2, 3]
;
Vanderborght, Bart
[5, 6]
;
Da Silva, Tereza Cristina
[1]
;
Barbisan, Luis Fernando
[3]
;
Andraus, Wellington
[7]
;
Devisscher, Lindsey
[6]
;
Camara, Niels Olsen Saraiva
[8]
;
Vinken, Mathieu
[4]
;
Cogliati, Bruno
[1]
Total Authors: 12
|
| Affiliation: | [1] Univ Sao Paulo, Sch Vet Med & Anim Sci, Dept Pathol, BR-05508270 Sao Paulo - Brazil
[2] Sao Paulo State Univ UNESP, Botucatu Med Sch, Dept Pathol, BR-18618687 Botucatu, SP - Brazil
[3] Sao Paulo State Univ UNESP, Biosci Inst, Dept Struct & Funct Biol, BR-18618689 Botucatu, SP - Brazil
[4] Vrije Univ Brussel, Dept Pharmaceut & Pharmacol Sci, B-1090 Brussels - Belgium
[5] Univ Ghent, Fac Med & Hlth Sci, Gut Liver Immunopharmacol Unit, Liver Res Ctr Ghen, Basic & Appl Med Sci, B-9000 Ghent - Belgium
[6] Univ Ghent, Fac Med & Hlth Sci, Liver Res Ctr Ghent, Hepatol Res Unit, Internal Med & Paediat, B-9000 Ghent - Belgium
[7] Univ Sao Paulo HC FMUSP, Clin Hosp, Dept Gastroenterol, Sch Med, BR-05403000 Sao Paulo - Brazil
[8] Univ Sao Paulo, Inst Biomed Sci 4, Dept Immunol, BR-05508000 Sao Paulo - Brazil
Total Affiliations: 8
|
| Document type: | Review article |
| Source: | CANCERS; v. 13, n. 21 NOV 2021. |
| Web of Science Citations: | 0 |
| Abstract | |
Simple Summary</p> Hepatocellular carcinoma (HCC) is a highly incident and deadly malignant neoplasia, and only a few anti-HCC drugs are currently available. Thus, the development of HCC models has become essential for both basic and translational research, improving the understanding of HCC pathophysiology and molecular landscape. The present paper provides a state-of-the-art overview of in vivo and in vitro models used for translational modeling of HCC, focusing on their molecular hallmarks. Our paper depicts the key features, advantages and disadvantages of the main bioassays available, shedding light on standard HCC model choice.</p> Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third leading cause of cancer-related death globally. HCC is a complex multistep disease and usually emerges in the setting of chronic liver diseases. The molecular pathogenesis of HCC varies according to the etiology, mainly caused by chronic hepatitis B and C virus infections, chronic alcohol consumption, aflatoxin-contaminated food, and non-alcoholic fatty liver disease associated with metabolic syndrome or diabetes mellitus. The establishment of HCC models has become essential for both basic and translational research to improve our understanding of the pathophysiology and unravel new molecular drivers of this disease. The ideal model should recapitulate key events observed during hepatocarcinogenesis and HCC progression in view of establishing effective diagnostic and therapeutic strategies to be translated into clinical practice. Despite considerable efforts currently devoted to liver cancer research, only a few anti-HCC drugs are available, and patient prognosis and survival are still poor. The present paper provides a state-of-the-art overview of in vivo and in vitro models used for translational modeling of HCC with a specific focus on their key molecular hallmarks.</p> (AU) | |
| FAPESP's process: | 16/14420-0 - miRNA expression in Fibrosis-associated Hepatocarcinogenesis: Modulation by Caffeine, Trigonelline and Chlorogenic Acid. |
| Grantee: | Luís Fernando Barbisan |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 16/12015-0 - Caffeine, Trigonelline and Chlorogenic Acid: Modulation of miRNA expression in Fibrosis-associated Hepatocarcinogenesis. |
| Grantee: | Guilherme Ribeiro Romualdo |
| Support Opportunities: | Scholarships in Brazil - Doctorate |
| FAPESP's process: | 18/10953-9 - Are connexins, pannexins and their (hemi)channels novel biomarkers and pharmacological targets in the prognosis and therapy of liver cancer? |
| Grantee: | Bruno Cogliati |
| Support Opportunities: | Regular Research Grants |